VICTORIA, British Columbia / Oct 21, 2024 / Business Wire / ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced that Dr. Dirk Van Hyfte, Head of Innovation at BioStrand, IPA’s AI subsidiary, will participate on a Fireside Chat during the AI Driven Drug Discovery Summit USA 2024 taking place at the Aloft Boston Seaport District Hotel, Boston, Massachusetts, November 12-14, 2024.
AI Driven Drug Discovery Summit
Date: Thursday, November 14
Time: 11:30 pm EST
Format: Fireside Chat
To register for the event, please click Here
Meet with us
For appointment scheduling, please contact Jennifer K. Zimmons, PhD, MBA, at Quantum Media: This email address is being protected from spambots. You need JavaScript enabled to view it., +1.917.214.3514.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”).
| Last Trade: | US$0.41 |
| Daily Change: | -0.003 -0.73 |
| Daily Volume: | 108,779 |
| Market Cap: | US$12.670M |
March 28, 2025 February 26, 2025 February 24, 2025 January 27, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
